RegeneRx Biopharmaceuticals has received an issued patent in Mexico and allowances of three additional patent applications in Mexico and Israel, related to Thymosin beta 4 (Tβ4).
The patents are set to expire 2024-2026, the company said.
The Mexican patent covers the uses of Tβ4 to treat or prevent biological or immunological responses to reactive chemical or biological agents, or toxins.
Three separate applications in Mexico also have received notification of allowance which will cover uses of Tβ4 for elevated intraocular pressure and dry eye, congestive heart failure, and damage resulting from increases in blood flow.
The Israeli patent will cover uses of Tβ4 and Tβ4 fragments for use in various neuromuscular conditions.